Director’s Shareholding – PCA Dealing, Diaceutics PLC, 2020-05-05
Diaceutics PLC
(“Diaceutics” or the “Company”)
5 May 2020
Director’s Shareholding – PCA Dealing
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces that Delia Keeling, wife of Peter Keeling, Chief Executive of Diaceutics, has transferred a total of 24,000 ordinary shares in the Company held by her to certain members of her family for nil consideration. The transfers were effected on 21 April 2020.
The following additional information is disclosed in accordance with article 19(3) of the Market Abuse Regulation.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||
a. | Name | Delia Keeling | |||||
2 | Reason for notification |
| |||||
a. | Position/Status | Wife of Peter Keeling, Chief Executive Officer of Diaceutics plc | |||||
b. | Initial notification/ Amendment | Initial | |||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
a. | Name | Diaceutics plc | |||||
b. | LEI | 213800VEWQBB39ZB8J81 | |||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
a. | Description of the financial instrument, type of instrument Identification Code | Ordinary shares of 0.2p each
ISIN: GB00BJQTGV64 | |||||
b. | Nature of the transaction | Transfer of shares to certain family members for nil consideration. The transfer comprised 1,000 shares each transferred to 24 individuals, all for nil consideration. | |||||
c. | Price(s) and volume(s) | ||||||
Price(s) | Volume(s) | ||||||
Nil | 24,000 | ||||||
| |||||||
e. | Date of the transaction | 21 April 2020 | |||||
f. | Place of the transaction | Outside a trading venue | |||||
Enquiries:
Diaceutics PLC | |||
Peter Keeling, Chief Executive Officer | via Walbrook PR | ||
Philip White, Chief Financial Officer |
| ||
|
| ||
Cenkos Securities plc (Nominated adviser and broker) | +44 (0) 20 7391 8900 | ||
Callum Davidson / Giles Balleny |
| ||
Michael Johnson (Sales) |
| ||
|
| ||
Walbrook PR | Tel: +44 (0)20 7933 8780 or [email protected] | ||
Anna Dunphy | Mob: +44 (0)7876 741 001 | ||
Paul McManus | Mob: +44 (0)7980 541 893 | ||
|
|
|
|
About Diaceutics
Diaceutics PLC is the diagnostic commercialisation company for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 35 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com
END
DSHSSUFSIESSEFI
Leave a Reply